Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04404712 · ClinicalTrials.gov registry record · Early Phase 1
FAAH Availability in Psychiatric Disorders: A PET Study
A Early Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT04404712 is a Early Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 6 participants.
The verdict
NCT04404712, a Early Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The aim of the present study is to examine Fatty Acid Amide Hydrolase (FAAH) availability in humans, including healthy individuals and across a spectrum of psychiatric disorders in which alterations in the endocannabinoid system are observed.
Interventions
- DRUG [11C]MK-3168
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-09-23 |
| Est. Completion | 2021-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04404712
The ClinicalTrials.gov registry entry for NCT04404712 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [11C]MK-3168 is the first listed.
NCT04404712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04404712 about?
NCT04404712 is a clinical study titled "FAAH Availability in Psychiatric Disorders: A PET Study". The aim of the present study is to examine Fatty Acid Amide Hydrolase (FAAH) availability in humans, including healthy individuals and across a spectrum of psychiatric disorders in which alterations in the endocannabinoid system are observed.
What is the current status of trial NCT04404712?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2020-09-23. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT04404712?
The interventions under investigation include: [11C]MK-3168 (DRUG).
Who is sponsoring clinical trial NCT04404712?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.